Oncology therapy programs utilizing the latest immune mediated technology have exploded over the last decade. With the advance of checkpoint inhibitors, new and different molecular diagnostic tests, and more recently, engineered cell therapies, vast new avenues have opened up to effectively treat greater numbers of patients. Kineticos’ Operating Executive, Steve Buckanavage, caught up with Dr. Jeffrey Skolnik, VP of Clinical Development at Inovio Pharmaceuticals to discuss some of these very topics.

Click here to download the full article: Bridges and Barriers to Advancing CAR-T Therapy

NOTE: Use your cursor to scroll or the tool-bar located at the bottom of this article to review all available pages.

Bridges and Barriers to Advancing CAR-T Therapy - Part 1